European Advisory Committee Recommends Approval of Erleada for Men at Risk of Prostate Cancer Spreading

European Advisory Committee Recommends Approval of Erleada for Men at Risk of Prostate Cancer Spreading
Janssen's hormone therapy Erleada (apalutamide) may soon be used in Europe for men with castration-resistant prostate cancer (CRPC) who have a high risk of their disease spreading, after the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency recommended its approval. The European Commission will now review CHMP’s recommendation before making a final decision. “We are pleased with the CHMP’s decision to recommend approval of apalutamide for the treatment of patients with high-risk, non-metastatic, castration-resistant prostate cancer,” Ivo Winiger-Candolfi, MD, lead of Janssen Oncology solid tumor therapy area in Europe, Middle East, and Africa, Cilag GmbH International, said in a press release. “We know that each prostate cancer patient journey is unique and today’s positive CHMP opinion brings us one step closer to offering patients an effective treatment option that delays the spread of their disease,” he said. Metastasis is a major cause of complications and death among men with prostate cancer. Nearly all men who die from the condition first see their disease spread to distant parts of the body. Thus, researchers have been focusing on the prevention of metastasis in men at risk, which may significantly extend their lives and improve their quality of life. Erleada is an
Subscribe or to access all post and page content.

One comment

  1. Colin Hannaford says:

    Is it possible that the prostate becomes enlarged in older men – and cancer becomes more likely – BECAUSE their testosterone levels have fallen?

Leave a Comment

Your email address will not be published. Required fields are marked *